TIG Advisors’s Prevail Therapeutics PRVL Stock Holding History
Bought
Maintained
Sold
TIG Advisors's PRVL Position: Q1 2021 in Review
TIG Advisors sold out of Prevail Therapeutics (PRVL) in Q1 2021, closing a stake of 709,282 shares — an estimated $16.4M sold.
TIG Advisors first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $16.4M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.
- TIG Advisors reported no remaining Prevail Therapeutics position as of Q1 2021 after selling out during the quarter.
- TIG Advisors sold 709,282 Prevail Therapeutics shares in Q1 2021, an estimated $16.4M.
- TIG Advisors first reported a position in Prevail Therapeutics in Q4 2020 and held it in 1 quarter.
- TIG Advisors's Prevail Therapeutics position peaked at $16.4M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Prevail Therapeutics as of Q1 2021.
Based on TIG Advisors's 13F filing for Q1 2021, filed 18 May 2021.